Hizentra Liquid
Product Images NDC 44206-458

Product Visual Gallery

This gallery contains 46 technical images submitted to the FDA as part of the official labeling for Hizentra (NDC 44206-458). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Csl Behring Ag, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Hizentra 01)

Instructional illustration showing the preparation of Hizentra liquid for subcutaneous use, including the rinsing of a bottle or vial under running water in a sink, with a gloved hand handling the bottle.*

FDA Label Image

Figure 2 (Hizentra 02)

Hizentra 0.2 g/mL liquid for subcutaneous administration is shown in a prefilled syringe with a product label attached. The syringe contains the plasma derivative human immunoglobulin G and is labeled by CSL Behring AG.*

FDA Label Image

Figure 3 (Hizentra 03)

A black and white photograph showing a gloved hand holding a small vial, demonstrating handling of a liquid medication vial. The vial appears clear with a label, but no legible text is visible. The image likely illustrates proper preparation or handling of Hizentra, a subcutaneous liquid immunoglobulin product.*

FDA Label Image

Figure 4 (Hizentra 04)

Hizentra 0.2 g/mL subcutaneous liquid human immunoglobulin G in a single-use vial with an attached syringe, displayed in a clear plastic tray. The vial and syringe are prefilled and sealed, intended for subcutaneous injection. Labeler is CSL Behring AG.*

FDA Label Image

Figure 5 (Hizentra 05)

Hizentra 0.2 g/mL subcutaneous liquid human immunoglobulin G in a vial or syringe packaging tray. The image shows two clear containers, one transparent and one dark, placed side by side in a molded plastic tray, intended for safe transport and administration. Labeler CSL Behring AG is associated with this plasma derivative product.*

FDA Label Image

Figure 6 (Hizentra 06)

The image shows a gray plastic connector device attached to a translucent tube or vial component, likely part of the Hizentra subcutaneous infusion system. The device appears designed for secure attachment and flow control of the liquid human immunoglobulin G (0.2 g/mL) formulation by CSL Behring AG.*

FDA Label Image

Figure 7 (Hizentra 07)

Hizentra 0.2 g/mL liquid subcutaneous human immunoglobulin G in a prefilled syringe. The label shows the proprietary and generic names, dosage form, and the labeler CSL Behring AG. The syringe features measurement markings and a transparent barrel with a gray plunger.*

FDA Label Image

Figure 8 (Hizentra 08)

An instructional image showing hands preparing a vial for medication administration. One hand holds the vial, while the other hand is handling a syringe or needle, illustrating a drug preparation procedure for subcutaneous liquid medication.*

FDA Label Image

Figure 9 (Hizentra 09)

An instructional illustration showing a person holding a syringe and a vial or medication device card, likely demonstrating preparation or administration steps, related to the medication Hizentra (human immunoglobulin G) liquid for subcutaneous use.*

FDA Label Image

Figure 10 (Hizentra 10)

An instructional image showing a person preparing medication by drawing liquid from a vial into a syringe, demonstrating the subcutaneous administration process commonly associated with products like Hizentra (Human Immunoglobulin G). The focus is on the hands holding the syringe and vial, illustrating proper handling technique.*

FDA Label Image

Figure 11 (Hizentra 11)

An instructional image showing a person using both hands to transfer liquid from a vial into a syringe. The image is related to the preparation or administration of a liquid medication, highlighting the handling technique with gloved hands.*

FDA Label Image

Figure 12 (Hizentra 12)

An instructional illustration showing hands holding and preparing a subcutaneous infusion set for administration, likely related to Hizentra (Human Immunoglobulin G) liquid subcutaneous use. The image depicts the setup and handling of tubing and connectors used in infusion.*

FDA Label Image

Figure 13 (Hizentra 13)

An illustration showing the front and back of a human torso with multiple marked sites on the abdomen and lower back. The marked sites likely indicate recommended subcutaneous injection locations for administering Hizentra (Human Immunoglobulin G) liquid.*

FDA Label Image

Figure 14 (Hizentra 14)

An instructional illustration shows a hand with a medical device attached to the finger, likely demonstrating a subcutaneous infusion or injection setup.*

FDA Label Image

Figure 15 (Hizentra 15)

An instructional photograph showing a person performing a subcutaneous injection in the abdominal area using a needle and syringe. The image illustrates proper hand positioning during the injection procedure, relevant for administering subcutaneous liquid medications like Hizentra (human immunoglobulin G).*

FDA Label Image

Figure 16 (Hizentra 16)

Hizentra 0.2 g/mL liquid human immunoglobulin G for subcutaneous use, packaged by CSL Behring AG. The image shows a transparent administration device with tubing and a connector, used for subcutaneous infusion.*

FDA Label Image

Figure 17 (Hizentra 17)

An instructional illustration showing a medical device used for subcutaneous administration of Hizentra (Human Immunoglobulin G) liquid formulation at 0.2 g/mL strength, by CSL Behring AG. The device appears to be a manual or automated infusion pump with a syringe attached, featuring control dials and slots for securing the syringe.*

FDA Label Image

Figure 18 (Hizentra 18)

FDA Label Image

Figure 19 (Hizentra 19)

Hizentra 0.2 g/mL subcutaneous liquid human immunoglobulin G plasma derivative container labeled by CSL Behring AG. The image shows a large plastic container with a biohazard symbol label and tubing being held above the container, likely for infusion setup.*

FDA Label Image

Figure 1 (Hizentra 20)

A Kaplan-Meier plot showing the probability of relapse or withdrawal over 26 weeks for placebo and two Hizentra subcutaneous liquid doses (0.2 g/kg and 0.4 g/kg). The graph compares relapse rates with placebo having the highest probability, followed by 0.2 g/kg and then 0.4 g/kg Hizentra dose.*

FDA Label Image

Figure 1 (Hizentra 21)

Illustration showing a person pouring a liquid from a plastic container into a sink, likely demonstrating preparation or disposal of the Hizentra 0.2 g/mL liquid subcutaneous human immunoglobulin G product.*

FDA Label Image

Figure 2 (Hizentra 22)

Hizentra 0.2 g/mL liquid subcutaneous injection in a prefilled syringe. The syringe is labeled with medication information including the proprietary name Hizentra and the active ingredient human immunoglobulin G. The product is manufactured by CSL Behring AG.*

FDA Label Image

Figure 3 (Hizentra 23)

Packaging image showing a gloved hand holding a small clear vial containing liquid, representing Hizentra, Human Immunoglobulin G injection, 0.2 g/mL subcutaneous liquid, labeled by CSL Behring AG.*

FDA Label Image

Figure 4 (Hizentra 24)

Hizentra 0.2 g/mL liquid human immunoglobulin G in a subcutaneous injection syringe. The image shows the syringe prefilled with the medication, packaged in a clear plastic container. The label on the syringe includes the product name and relevant identification, and the product is manufactured by CSL Behring AG.*

FDA Label Image

Figure 5 (Hizentra 25)

Hizentra 0.2 g/mL subcutaneous liquid solution in a prefilled syringe. The image shows the syringe within its protective plastic packaging, labeled for HUMAN IMMUNOGLOBULIN G. The product is manufactured by CSL Behring AG.*

FDA Label Image

Figure 6 (Hizentra 26)

Hizentra liquid subcutaneous delivery device component shown, associated with human immunoglobulin G 0.2 g/mL by CSL Behring AG. The image displays a small, clear plastic connector piece with a gray plastic clip, used in the administration system for this plasma derivative.*

FDA Label Image

Figure 7 (Hizentra 27)

Hizentra 0.2 g/mL subcutaneous liquid formulation in a prefilled syringe. The syringe has measurement markings and a white label with text detailing product information. The labeler is CSL Behring AG. The image shows the syringe filled with the liquid, intended for subcutaneous administration.*

FDA Label Image

Figure 8 (Hizentra 28)

An instructional illustration showing a person’s hands holding and manipulating a syringe connected to a vial or container, likely demonstrating how to prepare or administer a subcutaneous liquid medication such as Hizentra (Human Immunoglobulin G).*

FDA Label Image

Figure 9 (Hizentra 29)

An instructional illustration showing hands preparing a dose of Hizentra (human immunoglobulin G) liquid for subcutaneous injection. The image focuses on the vial and syringe handling process, demonstrating medication preparation for subcutaneous administration.*

FDA Label Image

Figure 10 (Hizentra 30)

An instructional black and white photograph showing a person preparing a syringe, likely for a subcutaneous injection. The individual is holding a vial with one hand and a syringe with the other, drawing liquid from the vial. This image illustrates the preparation step for administering a liquid medication such as Hizentra (human immunoglobulin G) subcutaneous injection.*

FDA Label Image

Figure 11 (Hizentra 31)

An instructional illustration showing a person preparing a syringe for subcutaneous injection. The image highlights hand positioning and syringe handling technique without product packaging or labeling visible.*

FDA Label Image

Figure 12 (Hizentra 32)

An instructional illustration showing hands holding a subcutaneous infusion set assembly, including tubing connected to a liquid delivery device. This likely depicts the equipment used for subcutaneous administration of Hizentra (Human Immunoglobulin G) liquid product.*

FDA Label Image

Figure 13 (Hizentra 33)

An anatomical diagram showing front and back views of a human torso with highlighted subcutaneous injection sites. The illustration marks areas on the abdomen and upper thighs at the front, and the lower back at the back, indicating potential sites for subcutaneous administration of the liquid product Hizentra (human immunoglobulin G).*

FDA Label Image

Figure 14 (Hizentra 34)

An instructional image showing a hand with a subcutaneous infusion catheter inserted, likely related to administration of Hizentra (human immunoglobulin G) liquid for subcutaneous use. The catheter and adhesive patch securing it to the skin are clearly visible.*

FDA Label Image

Figure 15 (Hizentra 35)

An instructional black-and-white illustration showing hands manipulating a subcutaneous infusion set. The image focuses on the positioning and connection of a small tubular device used for administering liquid medication, likely related to subcutaneous infusion techniques.*

FDA Label Image

Figure 16 (Hizentra 36)

FDA Label Image

Figure 17 (Hizentra 37)

Hizentra 0.2 g/mL, liquid human immunoglobulin G for subcutaneous administration. The image shows a clear prefilled syringe with a pinkish liquid inside, attached to a white plastic delivery device, labeled by CSL Behring AG.*

FDA Label Image

Figure 18 (Hizentra 38)

FDA Label Image

Figure 19 (Hizentra 39)

Hizentra 0.2 g/mL human immunoglobulin G liquid for subcutaneous use in a large rectangular container. The packaging features a white circular cap with a person's hand holding tubing above it. The label includes text and hazard symbols, identifying the product as a plasma derivative from CSL Behring AG.*

FDA Label Image

Principal Display Panel (5 mL Vial Carton)

Hizentra 1 g/5 mL single-dose vial carton label showing Immune Globulin Subcutaneous (Human), 20% Liquid. The label indicates subcutaneous administration only, includes storage instructions, ingredient details, the labeler CSL Behring AG, and distribution information by CSL Behring LLC. The carton design includes dosing and handling directions, barcodes, and patent and regulatory details.*

FDA Label Image

Principal Display Panel (10 mL Vial Carton)

Carton label for Hizentra 2 g/10 mL single-dose vial containing Immune Globulin Subcutaneous (Human) 20% Liquid. The packaging label includes dosage form liquid, route subcutaneous, and manufacturer CSL Behring AG. The label indicates the vial contains 2 g immunoglobulin in 10 mL solution, storage instructions, and usage directions for subcutaneous administration only.*

FDA Label Image

Principal Display Panel (20 mL Vial Carton)

Hizentra 4 g (0.2 g/mL) Immune Globulin Subcutaneous (Human) 20% Liquid single-dose vial carton. The label shows dosage form as liquid for subcutaneous administration only, manufactured by CSL Behring AG. The package contains one 20 mL vial with a total of 4 g immunoglobulin (human). Various storage and handling instructions, contents, and manufacturer details are included.*

FDA Label Image

Principal Display Panel (50 mL Vial Carton)

Packaging label for Hizentra 20% Liquid (Immune Globulin Subcutaneous (Human)), single-dose vial, 10 g in 50 mL. The label includes product name, strength, dosage form, and usage instructions for subcutaneous administration. It also provides storage information, manufacturer CSL Behring AG (Bern, Switzerland), and distributor CSL Behring LLC (Kankakee, IL, USA). Contains barcodes and regulatory information.*

FDA Label Image

Principal Display Panel (5 mL Syringe Carton)

The image shows the packaging label for Hizentra, Immune Globulin Subcutaneous (Human), 20% Liquid, a single-dose prefilled syringe for subcutaneous administration. The box displays the strength as 1 g in a 5 mL liquid form and is labeled for prescription use only. The labeler is CSL Behring AG.*

FDA Label Image

Principal Display Panel (10 mL Syringe Carton)

Hizentra 2 g (20% Liquid) Immune Globulin Subcutaneous (Human) single-dose prefilled syringe packaging label. The label indicates the product is for subcutaneous administration only and is manufactured by CSL Behring AG. The syringe volume is 10 mL.*

FDA Label Image

Principal Display Panel (20 mL Syringe Carton)

Box packaging label for Hizentra 4 g subcutaneous liquid injection. The product is Immune Globulin Subcutaneous (Human), 20% Liquid in a single-dose prefilled syringe for subcutaneous administration only. The labeler is CSL Behring AG. The box includes dosage and usage instructions along with barcodes and product identifiers.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.